Awareness regarding the risk of pancreatitis linked to DPP-4 inhibitors was demonstrated by 76.4% of physicians, and 90.1% acknowledged their safe use in patients with chronic kidney disease (CKD). This evidence concerns the gene DPP4 and chronic kidney disease.